Biogen shares soar on Alzheimer's drug developments
September 28, 2022 at 10:16 AM EDT
A study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over an 18-month period.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Copyright 2024. BUSINESS INSURANCE HOLDINGS
